A. Tambaki

发表

Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.

A. Tsatsoulis, H. Milionis, M. Elisaf, 2005, Thyroid : official journal of the American Thyroid Association.

Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.

M. Elisaf, I. Gazi, A. Tambaki, 2005, Prostaglandins, leukotrienes, and essential fatty acids.

The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.M300129-JLR200

M. Elisaf, R. Kalaitzidis, A. Tambaki, 2003, Journal of Lipid Research.

Effect of Atorvastatin on the Concentration, Relative Distribution, and Chemical Composition of Lipoprotein Subfractions in Patients With Dyslipidemias of Type IIA and IIB

M. Elisaf, A. Achimastos, E. Bairaktari, 2003, Journal of Cardiovascular Pharmacology.

Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2

R. Wolfert, M. Kostapanos, M. Elisaf, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Laparoscopic surgery-induced changes in oxidative stress markers in human plasma

T. Trikalinos, D. Galaris, E. Tsimoyiannis, 2001, Surgical Endoscopy.

Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.

J. Goudevenos, M. Elisaf, E. Bairaktari, 2002, Journal of lipid research.

Serum Lipoprotein(a) Concentrations and Apolipoprotein(a) Isoforms: Association with the Severity of Clinical Presentation in Patients with Coronary Heart Disease

J. Goudevenos, M. Elisaf, L. Michalis, 2001, Journal of cardiovascular risk.

Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.

J. Goudevenos, L. Michalis, A. Tambaki, 1999, Cardiovascular research.

Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB

J. Goudevenos, M. Elisaf, E. Bairaktari, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins Published, JLR Papers in Press, March 1, 2003. DOI 10.1194/jlr.M200452-JLR200

M. Elisaf, E. Bairaktari, A. Tambaki, 2003, Journal of Lipid Research.

Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity

M. Elisaf, A. Tambaki, A. Tselepis, 2004, Journal of cardiovascular pharmacology and therapeutics.

Fenofibrate induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity associated with apo B-containing lipoproteins

M. Elisaf, A. Tambaki, A. Tselepis, 2003 .

Platelet Hyperaggregability to Platelet Activating Factor (PAF) in Non-ST Elevation Acute Coronary Syndromes

J. Goudevenos, L. Michalis, C. Katsouras, 2002, Current medical research and opinion.

Comparison of the Effects of Atorvastatin and Fenofibrate on Apolipoprotein B-Containing Lipoprotein Subfractions in Patients with Combined Dyslipidemia

M. Elisaf, E. Bairaktari, A. Tambaki, 2004 .

Effect of synthetic peptides corresponding to residues 313–332 of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3

J. Goudevenos, M. Elisaf, N. Biris, 2004 .

Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.

C. Sala, N. Tentolouris, A. Tambaki, 2003, Experimental and clinical endocrinology & diabetes.

Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.

J. Goudevenos, M. Elisaf, N. Biris, 2004, European journal of biochemistry.